27 related articles for article (PubMed ID: 15578350)
1. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
Mohanty U; Dixit NM
J Theor Biol; 2008 Apr; 251(3):541-51. PubMed ID: 18258267
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
[TBL] [Abstract][Full Text] [Related]
5. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
6. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
Leen C; Wat C; Nieforth K
Clin Infect Dis; 2004 Dec; 39(11):e119-21. PubMed ID: 15578350
[TBL] [Abstract][Full Text] [Related]
8. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
[TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
Cervia JS; Smith MA
Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
[TBL] [Abstract][Full Text] [Related]
10. Enfuvirtide: from basic investigations to current clinical use.
Joly V; Jidar K; Tatay M; Yeni P
Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
[TBL] [Abstract][Full Text] [Related]
11. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide (Fuzeon): the first fusion inhibitor.
Williams IG
Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]